Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 124 participants.

Also called NCT03047772

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 124 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03047772
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03047772. Randomized; triple masking; primary purpose treatment. Start 2018-03-06 (anticipated); primary completion 2018-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients
Acronym
TEAM-AMI
Condition
Stem Cell Transplantation
Condition
Angioplasty, Transluminal, Percutaneous Coronary
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Intensive Atorvastatin
Intervention (Drug)
Low dose BMMSC
Intervention (Drug)
Middle dose BMMSC
Intervention (Drug)
High dose BMMSC
Intervention (Drug)
Transplantation
Lead sponsor
Yuejin Yang (class: other)
Collaborator
Peking Union Medical College Hospital (class: other)
Collaborator
The First Hospital of Hebei Medical University (class: other)
Collaborator
Zunyi Medical College (class: other)

Record details

Record id
cardio:ct-nct03047772
Content hash
df635b02a4b0dc50dd402a750c946b07edffc28698cecd5159ed13a5a3260d33